These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 33945820)

  • 1. Clinically Relevant Activity of the Novel RASP Inhibitor Reproxalap in Allergic Conjunctivitis: The Phase 3 ALLEVIATE Trial.
    Clark D; Cavanagh B; Shields AL; Karpecki P; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Oct; 230():60-67. PubMed ID: 33945820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reproxalap Activity and Estimation of Clinically Relevant Thresholds for Ocular Itching and Redness in a Randomized Allergic Conjunctivitis Field Trial.
    Cavanagh B; Gomes PJ; Starr CE; Nichols KK; Brady TC
    Ophthalmol Ther; 2022 Aug; 11(4):1449-1461. PubMed ID: 35585427
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Phase 3 INVIGORATE Trial of Reproxalap in Patients with Seasonal Allergic Conjunctivitis.
    Starr CE; Nichols KK; Lang JR; Brady TC
    Clin Ophthalmol; 2023; 17():3867-3875. PubMed ID: 38105911
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Reproxalap Improves Signs and Symptoms of Allergic Conjunctivitis in an Allergen Chamber: A Real-World Model of Allergen Exposure.
    Clark D; Karpecki P; Salapatek AM; Sheppard JD; Brady TC
    Clin Ophthalmol; 2022; 16():15-23. PubMed ID: 35018093
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Time to onset and duration of action of the antihistamine bepotastine besilate ophthalmic solutions 1.0% and 1.5% in allergic conjunctivitis: a phase III, single-center, prospective, randomized, double-masked, placebo-controlled, conjunctival allergen challenge assessment in adults and children.
    Abelson MB; Torkildsen GL; Williams JI; Gow JA; Gomes PJ; McNamara TR;
    Clin Ther; 2009 Sep; 31(9):1908-21. PubMed ID: 19843481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized, double-masked comparison of olopatadine ophthalmic solution, mometasone furoate monohydrate nasal spray, and fexofenadine hydrochloride tablets using the conjunctival and nasal allergen challenge models.
    Spangler DL; Abelson MB; Ober A; Gotnes PJ
    Clin Ther; 2003 Aug; 25(8):2245-67. PubMed ID: 14512132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis.
    Abelson MB; Turner D
    Clin Ther; 2003 Mar; 25(3):931-47. PubMed ID: 12852709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bioequivalence of two formulations of ketotifen fumarate ophthalmic solution: a single-center, randomized, double-masked conjunctival allergen challenge investigation in allergic conjunctivitis.
    Torkildsen GL; Abelson MB; Gomes PJ
    Clin Ther; 2008 Jul; 30(7):1272-82. PubMed ID: 18691986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Onset and Broad Activity of Reproxalap in a Randomized, Double-Masked, Vehicle-Controlled Phase 2b Trial in Dry Eye Disease.
    Clark D; Tauber J; Sheppard J; Brady TC
    Am J Ophthalmol; 2021 Jun; 226():22-31. PubMed ID: 33529588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ocular itch relief with alcaftadine 0.25% versus olopatadine 0.2% in allergic conjunctivitis: pooled analysis of two multicenter randomized clinical trials.
    McLaurin EB; Marsico NP; Ackerman SL; Ciolino JB; Williams JM; Villanueva L; Hollander DA
    Adv Ther; 2014 Oct; 31(10):1059-71. PubMed ID: 25260889
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prolonged effectiveness of bepotastine besilate ophthalmic solution for the treatment of ocular symptoms of allergic conjunctivitis.
    Williams JI; Kennedy KS; Gow JA; Torkildsen GL; Abelson MB; Gomes PJ; McNamara TR;
    J Ocul Pharmacol Ther; 2011 Aug; 27(4):385-93. PubMed ID: 21649522
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Double-Masked Phase 2a Trial to Evaluate Activity and Safety of Topical Ocular Reproxalap, a Novel RASP Inhibitor, in Dry Eye Disease.
    Clark D; Sheppard J; Brady TC
    J Ocul Pharmacol Ther; 2021 May; 37(4):193-199. PubMed ID: 33450164
    [No Abstract]   [Full Text] [Related]  

  • 13. Comparison of ketotifen fumarate ophthalmic solution alone, desloratadine alone, and their combination for inhibition of the signs and symptoms of seasonal allergic rhinoconjunctivitis in the conjunctival allergen challenge model: a double-masked, placebo- and active-controlled trial.
    Crampton HJ
    Clin Ther; 2003 Jul; 25(7):1975-87. PubMed ID: 12946545
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 3 Randomized Study of Efficacy and Safety of a Dexamethasone Intracanalicular Insert in Patients With Allergic Conjunctivitis.
    McLaurin EB; Evans D; Repke CS; Sato MA; Gomes PJ; Reilly E; Blender N; Silva FQ; Vantipalli S; Metzinger JL; Gibson A; Goldstein MH
    Am J Ophthalmol; 2021 Sep; 229():288-300. PubMed ID: 33773984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of epinastine hydrochloride ophthalmic solution in allergic conjunctivitis by conjunctival cedar pollen allergen challenge.
    Fujishima H; Ohashi Y; Takamura E
    Ann Allergy Asthma Immunol; 2014 Oct; 113(4):476-81. PubMed ID: 25163405
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and tolerability of ophthalmic epinastine: a randomized, double-masked, parallel-group, active- and vehicle-controlled environmental trial in patients with seasonal allergic conjunctivitis.
    Whitcup SM; Bradford R; Lue J; Schiffman RM; Abelson MB
    Clin Ther; 2004 Jan; 26(1):29-34. PubMed ID: 14996515
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Phase 2 Exploratory Study of a Novel Interleukin-1 Receptor Inhibitor (EBI-005) in the Treatment of Moderate-to-Severe Allergic Conjunctivitis.
    Goldstein MH; Tubridy KL; Agahigian J; Furfine E; Magill M; Kovalchin J; Golden K; Zarbis-Papastoitsis G; Soong F; Salapatek AM; Sternberg G; Celniker A
    Eye Contact Lens; 2015 May; 41(3):145-55. PubMed ID: 25915834
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A placebo-controlled comparison of ketotifen fumarate and nedocromil sodium ophthalmic solutions for the prevention of ocular itching with the conjunctival allergen challenge model.
    Greiner JV; Minno G
    Clin Ther; 2003 Jul; 25(7):1988-2005. PubMed ID: 12946546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Evaluation of the efficacy of olopatadine hydrochloride 0.1% ophthalmic solution and azelastine hydrochloride 0.05% ophthalmic solution in the conjunctival allergen challenge model.
    Spangler DL; Bensch G; Berdy GJ
    Clin Ther; 2001 Aug; 23(8):1272-80. PubMed ID: 11558863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of comfort using olopatadine hydrochloride 0.1% ophthalmic solution in the treatment of allergic conjunctivitis in contact lens wearers compared to placebo using the conjunctival allergen-challenge model.
    Brodsky M; Berger WE; Butrus S; Epstein AB; Irkec M
    Eye Contact Lens; 2003 Apr; 29(2):113-6. PubMed ID: 12695716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.